Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
VERU | US
0.02
2.15%
Healthcare
Drug Manufacturers-Specialty & Generic
30/06/2024
04/10/2024
0.77
0.77
0.78
0.76
Veru Inc. a biopharmaceutical company focuses on developing medicines for the management of COVID-19 and breast and prostate cancers. Its commercial products comprise FC2 female condom/internal condom for the protection against unintended pregnancy and the transmission of sexually transmitted infections; and Entadfi a capsule for the treatment of urinary tract symptoms. The company's drug candidates under development include Enobosarm an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin which is phase 2b clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Enobosarm + abemaciclib combination therapy which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer. In addition its drug candidate also comprise Sabizabulin which is in Phase 3 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100 a GnRH antagonist peptide injection which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate which is in Phase 2b clinical trial for treating hot flashes; and Sabizabulin an oral microtubule disruptor with dual antiviral and anti-inflammatory to severe COVID-19 patients at risk for acute respiratory distress syndrome. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami Florida.
View LessStrong Revenue Growth (> 10%)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
25.1%1 month
32.2%3 months
59.1%6 months
109.9%-
117.65
3.01
0.36
0.21
-3.23
6.93
-
-65.04M
112.70M
112.70M
-
-279.44
-
18.30
-126.72
27.43
9.57
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.08
Range1M
0.17
Range3M
0.40
Rel. volume
0.61
Price X volume
214.74K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Aceto Corporation | ACET | Drug Manufacturers-Specialty & Generic | 1.42 | 117.01M | -4.70% | n/a | 8.14% |
Karyopharm Therapeutics Inc | KPTI | Drug Manufacturers-Specialty & Generic | 0.8874 | 110.64M | 0.40% | n/a | -148.05% |
Assertio Therapeutics Inc | ASRT | Drug Manufacturers-Specialty & Generic | 1.14 | 108.68M | 1.79% | n/a | 30.76% |
OptiNose Inc | OPTN | Drug Manufacturers-Specialty & Generic | 0.7107 | 107.16M | 5.95% | n/a | -294.40% |
Relmada Therapeutics Inc | RLMD | Drug Manufacturers-Specialty & Generic | 3.48 | 105.01M | 2.35% | n/a | 0.00% |
Benitec Biopharma Limited | BNTC | Drug Manufacturers-Specialty & Generic | 9.48 | 95.62M | -7.06% | n/a | 0.00% |
INC Research Holdings Inc | INCR | Drug Manufacturers-Specialty & Generic | 1.87 | 85.58M | 2.75% | n/a | 41.98% |
SCYNEXIS Inc | SCYX | Drug Manufacturers-Specialty & Generic | 1.44 | 54.51M | 0.70% | n/a | 25.73% |
Provectus Biopharmaceuticals Inc | PVCT | Drug Manufacturers-Specialty & Generic | 0.1014 | 42.58M | 4.54% | n/a | 0.00% |
DURECT Corporation | DRRX | Drug Manufacturers-Specialty & Generic | 1.24 | 38.49M | -7.46% | n/a | 318.92% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Unifi Inc | UFI | Textile Manufacturing | 6.74 | 123.04M | -2.46% | n/a | 52.56% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Culp Inc | CULP | Textile Manufacturing | 5.95 | 74.32M | -2.30% | n/a | 11.29% |
ILAG | ILAG | Building Products & Equipment | 1.0599 | 19.14M | -0.93% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.695 | 8.47M | -4.15% | n/a | 16.03% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.6199 | 5.90M | 6.82% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.33 | 5.20M | 0.03% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.3899 | 3.55M | -0.01% | n/a | 9.62% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 0.4859 | 2.44M | -9.19% | n/a | 0.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -3.23 | 17.21 | Cheaper |
Ent. to Revenue | 6.93 | 334.38 | Cheaper |
PE Ratio | - | 26.92 | - |
Price to Book | 3.01 | 12.15 | Cheaper |
Dividend Yield | - | 2.77 | - |
Std. Deviation (3M) | 59.08 | 68.34 | Par |
Debt to Equity | 0.36 | -1.00 | Expensive |
Debt to Assets | 0.21 | 0.48 | Cheaper |
Market Cap | 112.70M | 5.31B | Emerging |